Home Book reviews Contact

DISCLOSURE: When you click on links to various merchants on this site and make a purchase, this can result in this site earning a commission at no extra cost to you. Affiliate programs and affiliations include, but are not limited to, the eBay Partner Network, Amazon and Alibris.

A leader is best when people barely know he exists, when his work is done, his aim fulfilled, they will say: we did it ourselves.

Lao Tzu

One more random pick among 2000+ quotes

touch the result table below to hide quote

Search for "Keyword: 9789401072892 ,ISBN: 9789401072892, " ..
this may take at most 15 seconds ..
 
Search done, now sorting ..
Please share to
Our search for Keyword: 9789401072892 ,ISBN: 9789401072892, brought up 9 title(s), showing 1 - 9. 10 removed. Sorting by Price Ascending.
Save this search Show quote
Search for "ISBN: 9789401072892" at eBay
Please follow us on AddALL Facebook page twitter page
TITLE

SORT

change title size: 16
AUTHOR

SORT

change author size: 16
PRICE

16
Bookstore

SORT

16
DESCRIPTION

 

change description size: 16
Steven J. Mather
author size: 16
USD
133.99
price size: 16
AHA-BUCH GmbH /ZVAB
dealer size: 16
ISBN10: 9401072892, ISBN13: 9789401072892, [publisher: Springer Netherlands] Softcover Druck auf Anfrage Neuware - Printed after ordering - Radiophannaceutical research has recently undergone a major change in direction. In past years it has been concerned mainly with the development of perfusion tracers, the biodistribution of which reflect the regional blood flow to areas of major organs such as the heart and brain. However, a major new direction of interest now lies in the development of receptor-binding radio-tracers which can be used to perform in-vivo characterisation of diseased tissues and it is likely that much of the future research in this field will follow this direction. The difficulties in developing such tracers are considerable. The researcher must first identify a promising target for radiopharmaceutical development. High specific activity radioactive molecules must be designed and synthesised which will both bind to the target receptor with high affinity, and also have the physicochemical characteristics which will allow them to reach the target site in sufficient quantity while at the same time showing minimal uptake in non-target tissues. Thus the knowledge base required for radiophannaceutical development has now expanded beyond the limits of radiopharmaceutical chemistry to include aspects of biochemistry, molecular biology and conventional drug design. The portfolio of basic knowledge required to support current radiopharmaceutical development i ...
Show/Hide image
description size: 16
Steven J. Mather
USD
146.89
AHA-BUCH GmbH /AbebooksDE
ISBN10: 9401072892, ISBN13: 9789401072892, [publisher: Springer Netherlands] Softcover Druck auf Anfrage Neuware - Printed after ordering - Radiophannaceutical research has recently undergone a major change in direction. In past years it has been concerned mainly with the development of perfusion tracers, the biodistribution of which reflect the regional blood flow to areas of major organs such as the heart and brain. However, a major new direction of interest now lies in the development of receptor-binding radio-tracers which can be used to perform in-vivo characterisation of diseased tissues and it is likely that much of the future research in this field will follow this direction. The difficulties in developing such tracers are considerable. The researcher must first identify a promising target for radiopharmaceutical development. High specific activity radioactive molecules must be designed and synthesised which will both bind to the target receptor with high affinity, and also have the physicochemical characteristics which will allow them to reach the target site in sufficient quantity while at the same time showing minimal uptake in non-target tissues. Thus the knowledge base required for radiophannaceutical development has now expanded beyond the limits of radiopharmaceutical chemistry to include aspects of biochemistry, molecular biology and conventional drug design. The portfolio of basic knowledge required to support current radiopharmaceutical development i ...
Show/Hide image
Mather, Steven J (Editor)
USD
159.69
Alibris /Alibris
Dordrecht Springer 2011 Trade paperback New. Trade paperback (US). Glued binding. 240 p. Developments in Nuclear Medicine, 30.
Mather, Steven J (Editor)
USD
172.29
Ria Christie Books via Alibris /Alibris
Dordrecht Springer 2011 Trade paperback New. Trade paperback (US). Glued binding. 240 p. Developments in Nuclear Medicine, 30.
Mather, Steven J.
USD
178.25
Lucky's Textbooks /Abebooks
ISBN10: 9401072892, ISBN13: 9789401072892, [publisher: Springer] Softcover
[Dallas, TX, U.S.A.] [Publication Year: 2011]
Steven J. Mather
USD
182.83
Ria Christie Collections /Biblio
New. New Book; Fast Shipping from UK; Not signed; Not First Edition; The Current Directions in Radiopharmaceutical Research and Development. ISBN 9401072892 9789401072892 [GB]
Mather Steven J.
USD
218.55
Revaluation Books /Biblio
Springer, Date: 2012. Paperback. New. reprint edition. 260 pages. 9.44x6.31x0.59 inches. 2012. Springer ISBN 9401072892 9789401072892 [GB]
Mather, Steven J.
USD
221.91
Revaluation Books /AbebooksUK
ISBN10: 9401072892, ISBN13: 9789401072892, [publisher: Springer] Softcover reprint edition. 260 pages. 9.44x6.31x0.59 inches. In Stock.
[Exeter, United Kingdom] [Publication Year: 2012]
Mather, Steven J.
USD
258.39
dsmbooks /AbebooksUK
ISBN10: 9401072892, ISBN13: 9789401072892, [publisher: Springer] Softcover Like New
[liverpool, United Kingdom] [Publication Year: 2011]

DISCLOSURE: When you click on links to various merchants on this site and make a purchase, this can result in this site earning a commission at no extra cost to you. Affiliate programs and affiliations include, but are not limited to, the eBay Partner Network, Amazon and Alibris.


TOO Many Search Results? Refine it!
Exclude: (what you don't want)
Include: (what you want)
Search Results Sort By:
240419071546720006